|
Online Database of Chemicals from Around the World | Search | Submit | Advertise | |
Home >> Chemical Listing >> Tesofensine>> Market Analysis Reports |
Market Analysis Reports of Tesofensine |
|
Tesofensine (CAS 195875-84-4) Market Research Report 2025 BAC Reports offers its clients in-depth market research of chemical industry products on the global and regional markets (North & Latin America, Asia Pacific, European Union, Russia and CIS). Tesofensine Market Research Report 2025 BAC Reports offers its clients in-depth market research of chemical industry products on the global and regional markets (North & Latin America, Asia Pacific, European Union, Russia and CIS). Neurosearch A/S Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis ... clinical trial for Huntingtons disease; Tesofensine, which is in Phase III clinical trial ... Obesity - Pipeline Insight, 2021 ... NNC 01651875 Peptide YY BI 456906 LY 3305677 Tesofensine HDV Biotin BI 1356225 EMP16-02 AMG ... YH34160 YHC2129 YHC2134 CT 868 Metoprolol/tesofensine OPK-88003 KTX-0200 NovOB ... Hypothalamic Obesity (HO) - Pipeline Insight, 2019 This report can be delivered to the clients within 24 Hours "Hypothalamic Obesity (HO) - Pipeline Insight, 2019" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the ... Type2 Diabetes Mellitus- Pipeline Insight, 2022 ... Exenatide Topiramate LY3209590 HM12460A HM14220 Tesofensine/Metoprolol Ruboxistaurin Mesylate BMS-816336 ... Prader-Willi Syndrome (PWS) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Prader-Willi Syndrome (PWS) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Prader-Willi Syndrome (PWS) - Drugs in ... NeuroSearch AS (NEUR) - Financial and Strategic SWOT Analysis Review ... assets, and further development of NS2330 (tesofensine) and NS2359 as well as of any potential ... |